Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

18 mai 2018

02:22
This week, dosing was completed according to plan in the second clinical study with Immunosetm FLU, developed with the aim to become a modern and effective nasal influenza vaccine. - In the perspective of this year's severe influenza outburst we...


17 mai 2018

21:33
ReCor Medical announced today that it will present the primary outcomes data from the SOLO study of its RADIANCE Global Clinical Trial Program of the Paradise®  Ultrasound Renal Denervation System for patients with hypertension during the Late...

19:15
The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment...

19:00
From robotics and machine learning to new applications for MRIs, Keck School of Medicine of USC scientists will present research highlighting the impact of technology on patient outcomes and the field of urology at the American Urological Association...

16:00
Celularity, Inc. ("Celularity"), a biotechnology company that produces lifesaving cell therapies from the postpartum placenta, announces that it is sponsoring an investigative study on the use of its proprietary human placental derived stem cells...

14:42
Lustgarten Foundation Distinguished Scholar Douglas Fearon, M.D., a professor at Cold Spring Harbor Laboratory (CSHL), has discovered how pancreatic cancer metastasizes to the liver following surgery, as reported in today's online edition of leading...

14:32
The Department of Defense (DOD) today announced the award of nearly $5 million to 13 innovative and impactful lupus research projects through its new Lupus Research Program. The Lupus Foundation of America and its...

14:00
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic...

14:00
Scientists at Cold Spring Harbor Laboratory (CSHL) have solved a mystery about how pancreatic cancer spreads following surgery in patients whose tumor is successfully removed.   After surgery, patients' typically...

13:37
Agenus Inc. , an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) antibodies have shown...

13:11
For biopharmaceutical companies looking to streamline the clinical trial process, "big data" can be a big challenge. From complex genomics to the constant stream of patient data from mobile sensors and devices, the information supporting a modern...

12:30
Today, the American Urological Association (AUA), a leading global urology association, announced updates to its Castration-Resistant Prostate Cancer (CRPC) clinical guideline, to incorporate new published research related to the treatment of...

10:14
Protagonist Therapeutics, Inc. today announced that clinical and preclinical abstracts for PTG-300, the Company's injectable hepcidin mimetic in development for treatment of anemia and iron overload in rare blood disorders, have been accepted for...

10:11
The results of the PREPAReS clinical trial were published today in Blood, the official journal of the American Society of Hematology. The trial evaluated the effectiveness of buffy-coat-derived platelets in plasma treated by the Mirasol® Pathogen...

10:00
Today, the American Urological Association (AUA), a leading global urology association, released a new clinical guideline on the surgical management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)....

09:51
Boston Biomedical, Inc., an industry leader in the development of novel cancer therapeutics, today announced that it will feature several studies evaluating investigational compounds napabucasin and DSP-7888 at the upcoming 2018 American Society of...

09:35
Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the European Hematology Association...

09:15
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will present data at the 23rd Annual Congress of the European Hematology Association (EHA), to be held June 14-17, 2018 in...

09:01
Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that preliminary data from its ongoing Phase 1 clinical trial evaluating 5F9 as a...

09:00
Blueprint Medicines Corporation , a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced two data presentations supporting plans for rapid development of avapritinib, a...

09:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from a Phase 2 clinical trial assessing BL-8040 as a single agent for hematopoietic stem cell mobilization in an...

09:00
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data showing the lack of cardiac toxicity associated with treatment with partner NantCell's aldoxorubicin will be...

08:45
MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced...

08:30
Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of...

08:30
During the Congress of the American Society of Clinical Oncology (ASCO) that will be held form the 1st to the 5th of June in Chicago (USA), PharmaMar will present the data obtained from various clinical studies of the molecules Yondelis ®,...

08:08
Eisai Inc. today announced the presentation of new data and analyses at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5 in Chicago. The data to be presented include five abstracts on combination studies of...

08:00
Trovagene, Inc. , a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced the completion of the first dose cohort in its Phase 1b/2 clinical trial of...

07:30
Pharmazz, Inc. is pleased to announce interim analysis of a prospective, multi-centric, randomized, double-blind, parallel, saline controlled phase II study of PMZ-2010 (centhaquin) as a resuscitative agent for hypovolemic shock due to excessive...

07:00
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") , a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from multiple cohorts of the ongoing Phase 2 ENCORE 601...

07:00
Correvio Pharma Corp. , formerly Cardiome Pharma Corp., today announced that its partner Eddingpharm has enrolled the first patient in a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess® versus placebo in...

06:30
La qualité de l'air influence la fécondation in vitro   La pollution atmosphérique a des effets négatifs sur la santé, au niveau respiratoire, cardiovasculaire, dermatologique, etc. Le système reproductif n'est pas non plus épargné. Depuis 2002,...

05:30
DelMar Pharmaceuticals, Inc. ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third quarter ended March 31, 2018. DelMar executive management will...

03:31
The EFECT-study evaluated standard hormonal therapies for women with advanced breast cancer and DiviTum® was used as a non-invasive tool for monitoring therapy response. 244 patients had blood samples analyzed with DiviTum® in a collaboration between...


16 mai 2018

23:19
Not intended for UK- or US-based media  ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016;...

21:13
Not intended for UK-based media ASCO Abstract # Avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK):...

21:04
iSTAR Medical SA, une société privée de dispositifs médicaux développant des implants ophtalmiques innovants pour le traitement du glaucome, a annoncé aujourd'hui des résultats à six mois exceptionnels pour leur premier essai de chirurgie...

19:45
Nektar Therapeutics  today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, which is being held from June 1 to June 5, 2018, at the McCormick Place...

18:25
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 21 company-sponsored abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5. New data analyses in...

18:18
BerGenBio ASA (OSE: BGBIO) announces that the company and its collaborators will present new interim clinical and biomarker data from its extensive Phase II clinical development programme with bemcentinib, a selective, oral AXL...

17:17
Array BioPharma Inc. announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in advanced BRAF-mutant melanoma in an oral presentation on June 4, 2018, at the 54th Annual Meeting of the American Society of...

17:05
- Updated results from the large ongoing phase 1 study of DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in metastatic breast cancer, gastric cancer and other tumors with HER2 as cell surface target to be reported -...

17:00
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first positive Phase 1 clinical data assessing cemiplimab as a potential treatment for advanced non-small cell lung cancer (NSCLC) will be shared at the 2018 American Society of...

17:00
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that a wide selection of abstracts highlighting the Company's diverse oncology portfolio across a broad range of cancers have been accepted for...

17:00
Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a "high" and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of...

17:00
Eli Lilly and Company today announced that new results from a number of studies across the company's oncology product and pipeline portfolio will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago,...

16:02
Positive top line results from Phase 3 C-AXSPAND study underscore the potential of CIMZIA® (certolizumab pegol) for non-radiographic axial spondyloarthritis (nr-axSpA), and provide concrete evidence for the high burden of the disease and limitations...

14:42
Clearwater Florida's Hair & Scalp Clinic Confirmed the development of a New Laser Treatment, to Stop Hair Loss and Re-Grow Hair. The Clinic is seeking participants to use this New Technology (At No Cost) to document the results. The laser is totally...

11:30
Audentes Therapeutics, Inc. , a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced continuing positive data from the first dose...

11:03
BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study to replace painful bone marrow biopsies through a simple blood test for Acute Myeloid Leukemia. The larger study...

11:00
Among people with intermittently recurring atrial fibrillation who are not taking anti-blood-clotting medications, those whose hearts were in abnormal rhythms longer were three times more likely to have strokes or other types of blood clots than...

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20